Development of New Improved Perflutren Ultrasound Contrast Agent
新型改良Perflutren超声造影剂的研制
基本信息
- 批准号:9409654
- 负责人:
- 金额:$ 122.94万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-08-17 至 2020-03-31
- 项目状态:已结题
- 来源:
- 关键词:AcidsAdverse effectsAdverse eventAnimalsBack PainBlindedBolus InfusionChargeClinicalComplementComplement ActivationConeContrast MediaDefinityDevelopmentDoseEchocardiographyElectrostaticsEtiologyExcipientsFDA approvedFamily suidaeFormulationGeneric DrugsGoalsHydrolysisImageImageryInflammationInfusion proceduresIntravenous infusion proceduresIonizing radiationKidneyLabelLeadLegal patentLifeLipidsMediatingMembraneMicrobubblesModelingMyocardial perfusionOptisonOutcomes ResearchPalmitic AcidsPathway interactionsPatientsPhospholipidsPreparationProductionProgram DevelopmentResearch PersonnelResistanceSafetySickle Cell AnemiaSterilizationTemperatureTherapeuticTimeTranslatingUltrasonographyclinical developmentcostimaging studyimprovedmeetingsmolecular imagingperfusion imagingportabilityprogramsresearch and developmenttargeted imagingtheranosticsvolunteer
项目摘要
Three ultrasound contrast agents (Definity®, Optison® and Lumason®) are FDA approved for
echocardiography in the U.S. Definity currently has over 75% market share. Definity’s dominance in the market
is due to its ease of administration via IV infusion and robust ultrasound contrast. Definity® has shelf-life of 2
years and must be stored under refrigerated conditions. Definity has an unpleasant side effect of back pain in
about 2% of patients. In some groups, e.g. patients with sickle cell disease, the rate of side effects is much
higher, e.g. about 20%. The most likely etiology of the back pain is complement activation. Definity is stabilized
by three phospholipids one of which is dipalmitoylphosphatidic acid (DPPA). The investigators in this proposal
have shown that DPPA shortens the storage life of Definity and likely causes the side effect of the back pain.
Microvascular Therapeutics (MVT) has discovered that not only is DPPA the most rapidly hydrolyzed lipid in
the Definity formulation but that DPPA also accelerates the hydrolysis of the other lipids. When DPPA
hydrolyzes it forms lyso-PA - a potent stimulating molecule causing inflammation likely responsible for the
adverse side effects. MVT has invented a stable, neutral MB (MVT-100). Compared to Definity, MVT-100 is
four times more resistant to hydrolysis. In a model of complement-mediated renal retention MVT-100 had fewer
bioeffects than Definity – which should translate into significantly less adverse events. Echocardiography in
pigs shows that MVT-100 is comparable, if not superior to Definity, in providing LV opacification and
myocardial perfusion contrast. MVT has received guidance from the FDA that MVT-100 can be developed
via the 505(b)(2) pathway, no additional animal studies are required;; an accelerated clinical program
can be used to lead to approval. MVT-100 will serve as a platform for development of theranostics.
Specific Aims: 1. GMP manufacture MVT-100, file IND. 2. Dose ranging study in 32 volunteers (bolus and
infusion, Definity vs MVT-100)3. Pivotal study in 61 patients with suboptimal echocardiograms;; significant
improvement in LV border delineation in > 85% of subjects. 4. File NDA
Rationale: MVT-100 is an improved product. Perfluoropropane is the API and the lipids are excipients in the
product. The 505(b)(2) pathway allows for an accelerated approval pathway for such products. Upon NDA
submission, typical 11-month review period by the FDA before approval. The development pathway will yield
identical label claims as those for Definity. Additional label claims can be pursued later or in parallel.
Expected outcomes of research: Development of an FDA approved improved perflutren product, MVT-100
with longer shelf-life (potential for room temperature storage and terminal sterilization – increasing safety of the
product) and decreased adverse side effects. Since the product is electrostatically neutral, MVT-100 will also
serve as a robust platform for development of molecular imaging targeted ultrasound contrast agents
and theranostic agents.
三种超声造影剂(Definity®,Optison®和Lumason®)是FDA批准的
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
THOMAS R PORTER其他文献
THOMAS R PORTER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('THOMAS R PORTER', 18)}}的其他基金
Scar Detection and Treatment with Droplet Activation
通过液滴激活进行疤痕检测和治疗
- 批准号:
10376846 - 财政年份:2020
- 资助金额:
$ 122.94万 - 项目类别:
Scar Detection and Treatment with Droplet Activation
通过液滴激活进行疤痕检测和治疗
- 批准号:
10599954 - 财政年份:2020
- 资助金额:
$ 122.94万 - 项目类别:
Scar Detection and Treatment with Droplet Activation
通过液滴激活进行疤痕检测和治疗
- 批准号:
10133130 - 财政年份:2020
- 资助金额:
$ 122.94万 - 项目类别:
Scar Detection and Treatment with Droplet Activation
通过液滴激活进行疤痕检测和治疗
- 批准号:
9887727 - 财政年份:2020
- 资助金额:
$ 122.94万 - 项目类别:
Development of New Improved Perflutren Ultrasound Contrast Agent
新型改良Perflutren超声造影剂的研制
- 批准号:
9546839 - 财政年份:2017
- 资助金额:
$ 122.94万 - 项目类别:
Targeted Blood Brain Barrier Permeability Changes with Ultrasound & Microbubbles
超声有针对性地改变血脑屏障渗透性
- 批准号:
7487012 - 财政年份:2007
- 资助金额:
$ 122.94万 - 项目类别:
THERAPEUTIC APPLICATIONS OF MICROBUBBLES-PHASE II
微泡第二阶段的治疗应用
- 批准号:
6390069 - 财政年份:1998
- 资助金额:
$ 122.94万 - 项目类别:
THERAPEUTIC APPLICATIONS OF MICROBUBBLES-PHASE II
微泡第二阶段的治疗应用
- 批准号:
6207624 - 财政年份:1998
- 资助金额:
$ 122.94万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 122.94万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 122.94万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 122.94万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 122.94万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 122.94万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 122.94万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 122.94万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 122.94万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 122.94万 - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
$ 122.94万 - 项目类别:
Discovery Grants Program - Individual














{{item.name}}会员




